Celularity Inc. to Host Investor and Analyst Research & Development Day
FLORHAM PARK, N.J., April 22, 2024 (GLOBE NEWSWIRE) -- Celularity Inc. (NASDAQ:CELU) ("Celularity"), a regenerative and cellular medicine company developing placental-derived allogeneic cell therapies and advanced
GlobeNewswireApr 22 08:00 ET
Express News | Celularity Inc. Announces Receipt of Nasdaq Notice Regarding Late Form 10-K Filing
Moomoo 24/7Apr 19 17:30 ET
Celularity Abstract "Emerging Technologies for the Management and Protection of Tendon Injuries: Decellularized Placental Biomaterials" Accepted at ORS Tendon Conference 2024
Celularity Inc. (Nasdaq: CELU) today announced that its abstract entitled "Emerging Technologies for the Management and Protection of Tendon Injuries: Decellularized Placental Biomaterials" was accepted by the Orthopedic Research Society (ORS) Tendon Conference, which will be held from May 30 - June 1, 2024 at the Mayo Clinic in Rochester, MN.
GlobeNewswireApr 18 16:30 ET
Express News | Celularity Announces Net Sales Trending Ahead of Expectations for First Quarter 2024; Implements Planned 2024 SG&a Reductions and Manufacturing Ramp for Advanced Biomaterial Products
Moomoo 24/7Apr 15 08:00 ET
Celularity to Present Data Showing Senescent Cell Elimination by Off-the-Shelf Natural Killer Cells Derived From Human Placental Cells
Company Presenting at ASGCT Annual MeetingFLORHAM PARK, N.J., April 08, 2024 (GLOBE NEWSWIRE) -- Celularity Inc. (NASDAQ: CELU) ("Celularity"), a biotechnology company developing placental-derived a
GlobeNewswireApr 8 09:00 ET
Celularity Receives Healthcare Common Procedure Coding System (HCPCS) Q Code Approval From the U.S. Centers for Medicare & Medicaid Services for Biovance 3L
Nationally Established Q Code Will Further Support the Use of Biovance 3L by Physicians to Treat Wound Care Patients in Office SettingsFLORHAM PARK, N.J., March 26, 2024 (GLOBE NEWSWIRE) -- Celulari
GlobeNewswireMar 26 09:00 ET
Celularity Submits Request to U.S. FDA for Orphan Drug Designation for PDA-002 Asset Treating Facioscapulohumeral Muscular Dystrophy
FLORHAM PARK, N.J., March 20, 2024 (GLOBE NEWSWIRE) -- Celularity Inc. (NASDAQ:CELU) ("Celularity"), a regenerative medicine company developing placental-derived allogeneic cell therapies and advanced biomaterial
GlobeNewswireMar 20 09:15 ET
Celularity CEO to Present on Cell Therapy's Potential to Improve Longevity at 2024 ABUNDANCE Summit
FLORHAM PARK, N.J., March 14, 2024 (GLOBE NEWSWIRE) -- Celularity Inc. (NASDAQ:CELU) ("Celularity" or the "Company"), a biotechnology company developing placental-derived allogeneic cell therapies and biomaterial
GlobeNewswireMar 14 09:15 ET
Celularity CEO to Present Keynote Address at 2024 Society for Brain Mapping and Therapeutics Annual World Congress
FLORHAM PARK, N.J., March 12, 2024 (GLOBE NEWSWIRE) -- Celularity Inc. (NASDAQ:CELU) ("Celularity" or the "Company"), a biotechnology company developing placental-derived allogeneic cell therapies and biomaterial
GlobeNewswireMar 12 09:20 ET
Celularity to Present Data Showing Cancer Tumor Reduction by Off-the-Shelf Cell Therapy Derived From Human Placental Cells
FLORHAM PARK, N.J., March 07, 2024 (GLOBE NEWSWIRE) -- Celularity Inc. (NASDAQ:CELU) ("Celularity"), a biotechnology company developing placental-derived allogeneic cell therapies and biomaterial products, announced
GlobeNewswireMar 7 09:35 ET
Trading Halt: Halt Status Updated at 9:00:00 AM ET: Quotation Resumption: News and Resumption Times
Trading Halt: Halt Status Updated at 9:00:00 AM ET: Quotation Resumption: News and Resumption Times
BenzingaFeb 29 09:00 ET
Celularity Announces 1-for-10 Reverse Stock Split
Globe NewswireFeb 23 16:10 ET
Celularity's Tri-layer Decellularized, Dehydrated Human Amniotic Membrane Product Investigated as a Carrier of Induced Pluripotent Stem Cell Derived-Limbal Stem Cells in the Treatment of Severe Ocular Surface Disease
Yahoo FinanceFeb 14 16:05 ET
Celularity Inc. (NASDAQ:CELUW) Short Interest Up 19.2% in March
Celularity Inc. (NASDAQ:CELUW – Get Rating) saw a large increase in short interest during the month of March. As of March 15th, there was short interest totalling 8,700 shares, an increase of 19.2% f
Financial News LiveApr 1, 2023 17:32 ET
Short Interest in Celularity Inc. (NASDAQ:CELUW) Declines By 60.1%
Celularity Inc. (NASDAQ:CELUW – Get Rating) was the recipient of a significant decline in short interest in the month of February. As of February 28th, there was short interest totalling 7,300 shares,
kopsourceMar 12, 2023 23:23 ET
Celularity Inc. (NASDAQ:CELUW) Sees Large Growth in Short Interest
Celularity Inc. (NASDAQ:CELUW – Get Rating) was the recipient of a large growth in short interest in February. As of February 15th, there was short interest totalling 18,300 shares, a growth of 190.5
Defense WorldMar 1, 2023 01:53 ET
Celularity Inc. (NASDAQ:CELUW) Short Interest Down 12.5% in January
Celularity Inc. (NASDAQ:CELUW – Get Rating) was the target of a significant decrease in short interest in the month of January. As of January 31st, there was short interest totalling 6,300 shares, a
Financial News LiveFeb 17, 2023 18:31 ET
No Data
No Data